Literature DB >> 28527995

Effect of Aconitum coreanum polysaccharide and its sulphated derivative on the migration of human breast cancer MDA-MB-435s cell.

Yandong Zhang1, Wei Wu2, Lihua Kang3, Dehai Yu3, Chunshui Liu4.   

Abstract

Polysaccharides extracted from medicinal plants possess multiple functions. However, the inhibitory capacity of polysaccharides on the metastasis of breast cancer remains unclear. In the present study, we investigated the inhibitory activity of Aconitum coreanum polysaccharide (ACP1) and its sulphated derivative ACP1-s on migratory behaviour of human breast cancer cells MDA-MB-435s and evaluated the underlying molecular mechanism. The data from Transwell assay indicated that ACP1 and ACP1-s caused a significant inhibition of MDA-MB-435s cell migration in vitro. ACP1 and ACP1-s significantly impaired MDA-MB-435s cell migratory behaviour, and the accumulated distance and average velocity of ACP1- and ACP1-s-treated cells were reduced markedly. We also found ACP1 and ACP1-s treatment could affect dynamic remodeling of actin cytoskeleton, and suppress phosphorylation and activation of signalling molecules, attributing to anti-metastatic role of ACP1 and ACP1-s. These findings reveal a novel therapeutic potential of A. coreanum polysaccharide and its sulphated derivative for breast cancer metastasis.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aconitum coreanum; Breast cancer; Metastasis; Polysaccharide; Sulphated derivative

Mesh:

Substances:

Year:  2017        PMID: 28527995     DOI: 10.1016/j.ijbiomac.2017.05.084

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  1 in total

1.  Aqueous Extract and Polysaccharide of Aconiti Lateralis Radix Induce Apoptosis and G0/G1 Phase Cell Cycle Arrest by PI3K/AKT/mTOR Signaling Pathway in Mesangial Cells.

Authors:  Xingyao Li; Peng An; Yanhong Zhao; Zimo Cai; Bingyu Ye; Yafeng Wang; Wenfang Wang; Qi Gao; Liuyun Li; Tao Zhang; Xili Wu
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-22       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.